Neumora Therapeutics, Inc. Common Stock (NMRA) has a consensus analyst rating of Buy, based on 9 analysts covering the stock. Of those, 6 recommend buying, 1 recommend holding, and 2 recommend selling.
The analyst consensus price target for NMRA is $7.25, representing a +251.9% upside from the current price of $2.06. Price targets range from a low of $6.00 to a high of $8.00.
